Publicaciones en colaboración con investigadores/as de Universidad Autónoma de Madrid (19)

2024

  1. Gender-specific risk factors and outcomes of hyperkalemia in CKD patients: smoking as a driver of hyperkalemia in men

    Clinical Kidney Journal, Vol. 17, Núm. 1

2023

  1. B- and T-lymphocyte attenuator could be a new player in accelerated atherosclerosis associated with chronic kidney disease

    Clinical science (London, England : 1979), Vol. 137, Núm. 17, pp. 1409-1429

2021

  1. Correction to: Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies (Drugs, (2021), 81, 13, (1467-1489), 10.1007/s40265-021-01555-5)

    Drugs

  2. Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies

    Drugs, Vol. 81, Núm. 13, pp. 1467-1489

  3. Intravenous iron therapy and the cardiovascular system: risks and benefits

    Clinical Kidney Journal, Vol. 14, Núm. 4, pp. 1067-1076

2020

  1. IL‐17A as a potential therapeutic target for patients on peritoneal dialysis

    Biomolecules, Vol. 10, Núm. 10, pp. 1-36

  2. Protective role of renal proximal tubular alpha-synuclein in the pathogenesis of kidney fibrosis

    Nature Communications, Vol. 11, Núm. 1

  3. TRAF3 Modulation: Novel Mechanism for the Anti-inflammatory Effects of the Vitamin D Receptor Agonist Paricalcitol in Renal Disease

    Journal of the American Society of Nephrology, Vol. 31, Núm. 9, pp. 2026-2042

2019

  1. Atherosclerosis in chronic kidney disease: More, less, or just different?

    Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 39, Núm. 10, pp. 1938-1966

  2. Erratum to: Lipid management in patients with chronic kidney disease (Nature Reviews Nephrology, (2018), 14, 12, (727-749), 10.1038/s41581-018-0072-9)

    Nature Reviews Nephrology

  3. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA

    Nephrology Dialysis Transplantation, Vol. 34, Núm. 2, pp. 208-230

2018

  1. Association of FGF-2 concentrations with atheroma progression in chronic kidney disease patients

    Clinical Journal of the American Society of Nephrology, Vol. 13, Núm. 4, pp. 577-584

  2. Combination of biomarkers of vascular calcification and sTWEAK to predict cardiovascular events in chronic kidney disease

    Atherosclerosis, Vol. 270, pp. 13-20

  3. Epigenetic modification mechanisms involved in inflammation and fibrosis in renal pathology

    Mediators of Inflammation, Vol. 2018

  4. Lipid management in patients with chronic kidney disease

    Nature Reviews Nephrology, Vol. 14, Núm. 12, pp. 727-749

  5. Role of epidermal growth factor receptor (EGFR) and its ligands in kidney inflammation and damage

    Mediators of Inflammation, Vol. 2018

2015

  1. Impaired Vitamin D signaling in endothelial cell leads to an enhanced leukocyte-endothelium interplay: Implications for atherosclerosis development

    PLoS ONE, Vol. 10, Núm. 8

2012

  1. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy

    American Journal of Physiology - Renal Physiology, Vol. 302, Núm. 6

2011

  1. Globotriaosylsphingosine actions on human glomerular podocytes: Implications for Fabry nephropathy

    Nephrology Dialysis Transplantation, Vol. 26, Núm. 6, pp. 1797-1802